Boan Biotech (06955.HK): BA1203 (masked PD-1/IL-2) approved in China to conduct clinical trials

Zhito Finance APP News, Boan Biotech (06955.HK) announced that the Investigational New Drug (IND) application for its in-development PD-1/IL-2 antibody cytokine prodrug BA1203 has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, and is intended for development for the treatment of multiple solid tumors. To the company's knowledge, this investigational drug is the world's only PD-1/IL-2 molecule with high IL-2 receptor activity, a masking design, and PD-1 blockade.